Skip to main content
FDA panel unanimously recommends Mylan's breast cancer generic
7/14/2017

Mylan's trastuzumab, a generic version of Roche Holding's Herceptin indicated for treatment of breast cancer, has been unanimously recommended for approval by an FDA advisory committee. Regulatory authorities in Europe, Australia and Canada are also reviewing the drug.

Full Story: